Results

• All
• Video
• Audio
• Images

• Most recent

1–1 of 1 result for Phase 3b

• 

  Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

  Carl D. Regillo, MD

  Annual Meeting Talks

  2022